Immunological status of peripheral blood is associated with prognosis in patients with bone and soft-tissue sarcoma
-
- Youngji Kim
- Division of Musculoskeletal Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
-
- Eisuke Kobayashi
- Division of Musculoskeletal Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
-
- Yoshiyuki Suehara
- Department of Orthopedic Surgery, Juntendo University School of Medicine, Tokyo 113-8431, Japan
-
- Ayumu Ito
- Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo 104-0045, Japan
-
- Daisuke Kubota
- Division of Musculoskeletal Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
-
- Yoshikazu Tanzawa
- Division of Musculoskeletal Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
-
- Makoto Endo
- Division of Musculoskeletal Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
-
- Fumihiko Nakatani
- Division of Musculoskeletal Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
-
- Tetsuya Nakatsura
- Division of Cancer Immunotherapy, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center Hospital, Tokyo 104-0045, Japan
-
- Akira Kawai
- Division of Musculoskeletal Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
-
- Kazuo Kaneko
- Department of Orthopedic Surgery, Juntendo University School of Medicine, Tokyo 113-8431, Japan
-
- Shigehisa Kitano
- Division of Cancer Immunotherapy, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center Hospital, Tokyo 104-0045, Japan
この論文をさがす
説明
Immune-checkpoint inhibitors have shown promising antitumor effects against certain types of cancer. However, specific immune-checkpoint inhibitors for patients with sarcoma have yet to be identified, whereas the immunological status of peripheral blood in patients with bone sarcoma and soft-tissue sarcoma (STS) remains unknown. In addition, it is unclear whether the immunological status from the peripheral blood could be used as a prognostic indicator. Therefore, the present study aimed to clarify the immunological status of peripheral blood samples derived from patients with bone sarcoma and STS. Immune monitoring was performed using the peripheral blood samples of 61 patients with no metastasis of high-grade sarcoma. A total of 25 patients with metastatic sarcoma were used for comparison. A total of 41 immune cell subsets were analyzed using multicolor-flow cytometry. The patients that did not have metastasis demonstrated higher quantities of monocytic myeloid-derived suppressor cells (M-MDSCs) and T cell immunoglobulin and mucin domain-3 (Tim-3)
収録刊行物
-
- Oncology Letters
-
Oncology Letters 21 (3), 2021-01-18
Spandidos Publications
